| Revenue growth | 35.3% YoY in Q4; 28.2% YoY for full FY26. |
|---|---|
| Margins | Matured units at 29% EBITDA; group margin diluted to 21.1% by new units. |
| Demand visibility | Strong; IP volumes grew 17.9% YoY in Q4 FY26. |
| Management confidence | Confident in 10-12% EBITDA growth for Telangana cluster and new unit ramp-ups. |
Growth
FY26 revenue up 28.2% to INR 3,931cr; PAT declined to INR 242cr due to expansion costs and EBITDA erosion.
Outlook
Planned INR 1,500cr QIP to retire INR 1,000cr debt and fund greenfield projects in Karnataka, Kerala, and Tamil Nadu.
Risks
Delays in insurance empanelment for new hospitals; ongoing impact from Gulf War and domestic austerity measures.
Earnings Call filed with BSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹780.15
- Market cap
- ₹32,767 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 160.4×Sector 57.8×
- Promoter holding
- 32.50%-1.61% QoQ
- FII holding
- 14.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Share Pledge
Promoters pledged 2,80,08,979 equity shares (6.66%) to Catalyst Trusteeship as debenture trustee. The pledge secures existing debenture obligations with no new capital involved.
Krishna Institute of Medical Sciences Capacity Expansion
Krishna Institute of Medical Sciences Ltd entered an Operations and Management Agreement with Sarvottam Health Care Pvt Ltd for 5+5 years to manage their operations.
- Execution
- 5 years with an extension for a further period of 5 years
Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong EBITDA margins despite lower ARPOB compared to peers, driven by lean operational efficiency and high patient volumes.
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
KIMS reported strong Q1 FY27 results with consolidated operating revenue growth of 35.3% YoY and 9.8% QoQ, driven by expansion and higher occupancy in core clusters.
Krishna Institute of Medical Sciences Q1 FY27 Results: Net Profit ₹37.4 Cr, Down 56.0% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,180 Cr (+35.3% YoY) and net profit of ₹37.4 Cr (-56.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹37.4 Cr · -56.0% YoY
Krishna Institute of Medical Sciences Earnings Call: Key Takeaways
KIMS delivered FY26 revenue growth of 28.2% YoY, reaching ₹39,308 Mn. Expansion continues across Telangana, AP, Maharashtra, and Kerala with a vision to reach 8600+ beds.